Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 11.5% in March

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 45,300 shares, a decline of 11.5% from the March 15th total of 51,200 shares. Approximately 0.9% of the shares of the stock are sold short. Based on an average daily volume of 54,600 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of Alzamend Neuro

Several institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE purchased a new stake in shares of Alzamend Neuro during the 1st quarter valued at $35,000. Geode Capital Management LLC lifted its holdings in Alzamend Neuro by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 563,660 shares of the company’s stock worth $318,000 after buying an additional 37,910 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Alzamend Neuro in the 4th quarter worth $28,000. Charles Schwab Investment Management Inc. acquired a new position in Alzamend Neuro in the 4th quarter worth $30,000. Finally, HRT Financial LP acquired a new stake in shares of Alzamend Neuro in the 4th quarter valued at about $32,000. 49.61% of the stock is owned by hedge funds and other institutional investors.

Alzamend Neuro Price Performance

ALZN traded up $0.04 during trading on Tuesday, hitting $0.78. The company’s stock had a trading volume of 25,341 shares, compared to its average volume of 53,682. The firm’s 50 day moving average price is $0.95 and its 200-day moving average price is $1.36. The stock has a market cap of $5.36 million, a PE ratio of -0.81 and a beta of 0.02. Alzamend Neuro has a twelve month low of $0.74 and a twelve month high of $11.91.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.